[HTML][HTML] Functional, biophysical, and structural characterization of human IgG1 and IgG4 Fc variants with ablated immune functionality
Engineering of fragment crystallizable (Fc) domains of therapeutic immunoglobulin (IgG)
antibodies to eliminate their immune effector functions while retaining other Fc …
antibodies to eliminate their immune effector functions while retaining other Fc …
Targeting FcγRs to treat antibody-dependent autoimmunity
X Yu, AH Lazarus - Autoimmunity reviews, 2016 - Elsevier
Self-reactive antibodies represent a significant force in autoimmune disease induction. In
antibody-dependent autoimmune syndromes such as immune thrombocytopenia (ITP) …
antibody-dependent autoimmune syndromes such as immune thrombocytopenia (ITP) …
[HTML][HTML] Next-generation Fc receptor–targeting biologics for autoimmune diseases
AW Zuercher, R Spirig, AB Morelli, T Rowe… - Autoimmunity …, 2019 - Elsevier
In recent years, there has been a surge in the research and development of novel molecules
as potential therapeutic alternatives to traditional treatments (such as intravenous …
as potential therapeutic alternatives to traditional treatments (such as intravenous …
[HTML][HTML] High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields, AK Namenuk, K Hong, YG Meng… - Journal of Biological …, 2001 - ASBMB
Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated
immune responses with cellular effector functions. A high resolution map of the binding site …
immune responses with cellular effector functions. A high resolution map of the binding site …
[HTML][HTML] Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice
The antibody Fc region regulates antibody cytotoxic activities and serum half-life. In a
therapeutic context, however, the cytotoxic effector function of an antibody is often not …
therapeutic context, however, the cytotoxic effector function of an antibody is often not …
[HTML][HTML] Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies
M Tada, A Ishii-Watabe, T Suzuki, N Kawasaki - PloS one, 2014 - journals.plos.org
Antibody-dependent cellular cytotoxicity (ADCC) is one of the important mechanisms of
action of the targeting of tumor cells by therapeutic monoclonal antibodies (mAbs). Among …
action of the targeting of tumor cells by therapeutic monoclonal antibodies (mAbs). Among …
Combined Fc-protein-and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated …
R Repp, C Kellner, A Muskulus, M Staudinger… - Journal of …, 2011 - Elsevier
Protein-or glyco-engineering of antibody molecules can be used to enhance Fc-mediated
effector functions. ScFv-Fc fusion proteins (scFv-Fc) represent interesting antibody …
effector functions. ScFv-Fc fusion proteins (scFv-Fc) represent interesting antibody …
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions
In recent years, therapy with monoclonal antibodies has become standard of care in various
clinical applications. Despite obvious clinical activity, not all patients respond and benefit …
clinical applications. Despite obvious clinical activity, not all patients respond and benefit …
Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ …
JB Stavenhagen, S Gorlatov, N Tuaillon, CT Rankin… - Cancer research, 2007 - AACR
Monoclonal antibodies (mAb) are widely used in the treatment of non-Hodgkin's lymphoma
and autoimmune diseases. Although the mechanism of action in vivo is not always known …
and autoimmune diseases. Although the mechanism of action in vivo is not always known …
Engineering therapeutic antibodies for improved function
LG Presta, RL Shields, AK Namenuk… - Biochemical Society …, 2002 - portlandpress.com
The binding sites on human IgG1 for human Fcγ receptor (FcγR) I, FcγRIIa, FcγRIIb, FcγRIIIa
and neonatal FcR have been mapped. A common set of IgG1 residues is involved in binding …
and neonatal FcR have been mapped. A common set of IgG1 residues is involved in binding …